Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: What Is the Best Treatment for Gastric Cancer with Positive Peritoneal Lavage Cytology or Localized Peritoneum Metastasis?

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 3rd English edition. Gastric Cancer. 1998;1:10–24.

    Article  CAS  Google Scholar 

  2. Kodera Y, Ito S, Mochizuki Y, et al. Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer. 2012;15(3):335–7.

    Article  Google Scholar 

  3. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9: 215–21.

    Article  CAS  Google Scholar 

  4. Yamaguchi T, Takashima A, Nagashima K, et al. Efficacy of postoperative chemotherapy after resection that leaves no macroscopically visible disease of gastric cancer with positive peritoneal lavage cytology (CY1) or localized peritoneum metastasis (P1a): A multicenter retrospective study. Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-019-07697-x

    Article  PubMed  Google Scholar 

  5. Nakayama I, Chin K, Matsushima T, Takahari D, et al. Retrospective comparison of S 1 plus cisplatin versus S 1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis. Int J Clin Oncol. 2017;22:1060–8.

    Article  CAS  Google Scholar 

  6. Kano Y, Kosugi S, Ishikawa T, et al. Prognostic significance of peritoneal lavage cytology at three cavities in patients with gastric cancer. Surgery. 2015;158(6):1581–9.

    Article  Google Scholar 

  7. Yoshiaki Iwasaki, Masanori Terashima, Junki Mizusawa, et al. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501). 2018 ASCO Annual Meeting, J Clin Oncol. 2018;36(suppl; abstr 4046).

  8. Manzanedo I, Pereira F, Rihuete Caro C et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol. 2019;26:2615–21.

    Article  Google Scholar 

  9. Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018 Jul 1;36(19):1922–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Chemotherapy Center and Second Department of Internal Medicine, Osaka Medical College, Osaka, Japan

    Toshifumi Yamaguchi MD, PhD

  2. Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan

    Toshifumi Yamaguchi MD, PhD, Atsuo Takashima MD, PhD & Narikazu Boku MD, PhD

Authors
  1. Toshifumi Yamaguchi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atsuo Takashima MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Narikazu Boku MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atsuo Takashima MD, PhD.

Ethics declarations

Disclosures

Dr. Boku reports support from Ono and Taiho (research grant, honorarium) and from Bristol-Myers Squibb, Chugai, and Eli-Lilly (honorarium). The other authors report no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This ASO Author Reflections is a brief invited commentary on the article “Efficacy of Postoperative Chemotherapy after Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): a Multicenter Retrospective Study,” Ann Surg Oncol. (2019). https://doi.org/10.1245/s10434-019-07697-x.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamaguchi, T., Takashima, A. & Boku, N. ASO Author Reflections: What Is the Best Treatment for Gastric Cancer with Positive Peritoneal Lavage Cytology or Localized Peritoneum Metastasis?. Ann Surg Oncol 27 (Suppl 3), 737–738 (2020). https://doi.org/10.1245/s10434-019-08054-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-019-08054-8

Search

Navigation